KRAS and familial pancreatic carcinoma: For example, KRAS mutation is present in more than 90% of pancreatic cancer cases (Bailey et al., 2016) and controls both tumorigenesis and metabolic reprogramming (Ying et al., 2012; Son et al., 2013; Liou et al., 2016).